Szerző: " Tomuță Ioan"

Konferencia vagy workshop anyag

Iovanov Rareș Iuliu; Dobre Andrei Alexe; Crișan Andrea Gabriela; Iurian Sonia Meda; Tomuță Ioan: 3D printing of prolonged-release tablets containing felodipine : [abstract].

Toma Ioana; Barbălată Cristina; Tefas Lucia; Porfire Alina; Tomuță Ioan: Development and characterization of gemcitabine lipobeads : [abstract].

Crișan Andrea-Gabriela; Porfire Alina; Iurian Sonia; Casian Tibor; Rus Lucia; Tomuță Ioan: The broadening horizons of pharmaceutical 3D printing - simple strategies for complex formulations : [abstract].

Barbălată Cristina; Porfire Alina; Tefas Lucia; Vlase Laurian; Tomuță Ioan: The implementation of the QbD concept in the development of lipobeads loaded with gemcitabine: the screening study.

Tefas Lucia Ruxandra; Bogdan Cătălina; Porfire Alina; Digkas Tryfon; De Beer Thomas; Tomuță Ioan: Development of liposomal drug delivery system as a strategy for improving bioavailability and therapeutic efficacy, by design of experiments : a case study.

Suciu Stefana; Iurian Sonia; Ambrus Rita; Bogdan Cătălina; Tomuță Ioan: Milk oral lyophilisates with loratadine : screening for new excipients for paediatric use.

Crișan Andrea-Gabriela; Iurian Sonia; Bogdan Cătălina; Rus Lucia; Porfire Alina; Porav Sebastian; Ilyés Kinga; Tomuță Ioan: Personalized fused deposition modeling 3D printed (FDM-3DP) tablets : a quality by design (QbD) approach.

Illyés Kinga; Tomuță Ioan: 3D-printing by fused deposition modelling in pharmaceutics.

Crișan Andrea-Gabriela; Tomuță Ioan: Fused deposition modeling three-dimensional printing (FDM-3DP) of channelled tablets with Ketoprofen : design, development and pharmaceutical evaluation.

Máthé Rita; Casian Tibor; Tomuță Ioan: Multivariate modelling for investigating the impact of raw materials and process variability on high drug load immediate release tablets obtained through wet granulation.

Barbălată Cristina; Porfire Alina; Cherfan Anca; Loghin Felicia; Tomuță Ioan: QbD development of a liposomal co-formulation with Doxorubicin and Simvastatin for an enhanced antiproliferative effect on T47D-KBluc cell line.